| Description |
1 online resource (231 p.) |
| Series |
Issn Series |
|
Issn Series
|
| Contents |
Intro -- Half Title -- Series Page -- Title Page -- Copyright Page -- Contents -- About the Series -- The International Organization for Medical Physics -- List of Common Acronyms -- Contributors -- Acknowledgments -- Part 1: Introduction -- 1. What Is Radiotheranostics? -- 1.1 Definitions -- 1.2 Scope -- 1.3 Radiotheranostic Pairs -- 1.4 The Need for Patient-Individualized Dosimetry in Radionuclide Therapy -- 1.5 Conclusion -- References -- 2. History of Radionuclide Therapy and Theranostics -- 2.1 Introduction -- 2.2 Röntgen, Becquerel, and the Curies |
|
2.3 The Curie Institute and Other Early Uses of Radionuclide Therapy -- 2.4 Advances in Physics in the 1930s -- 2.5 Saul Hertz and the Birth of Radioiodine Therapy -- 2.6 Radionuclide Therapy since Saul Hertz, Theranostics and the Future -- 2.7 Conclusion -- References -- 3. Biological Principles behind Targeted Radionuclide Therapy for Cancer -- 3.1 A Brief Introduction to Biology of Cancer and Cancer Metastasis -- 3.1.1 Cancer Metastasis -- 3.1.2 A Note on Cancer Therapies -- 3.2 Targeting Mechanisms in Radionuclide Therapy -- 3.2.1 Radioligand Therapy -- 3.2.2 Radioimmunotherapy |
|
3.3 Molecular Targets for Targeted Radionuclide Therapy -- 3.3.1 Sodium Iodide Symporter -- 3.3.2 Somatostatin Receptor -- 3.3.3 Prostate-Specific Membrane Antigen -- 3.3.4 Epidermal Growth Factor Receptor -- 3.3.5 Fibroblast Activation Protein -- 3.3.6 Mucins -- 3.3.7 Integrins -- 3.3.8 CD133 -- 3.4 Specialized Targeting Mechanisms in Radionuclide Therapy -- Examples -- 3.4.1 Brachytherapy -- 3.4.1.1 32P OncoSil for Pancreatic Cancer -- 3.4.1.2 90Y-Microspheres for Liver Cancer (Radioembolization) -- 3.4.2 Lipiodol -- 3.4.2.1 131I-Lipiodol for HCC -- 3.4.3 MIBG |
|
3.4.3.1 131I-MIBG for Neuroendocrine Tumors -- 3.4.4 Elemental Accumulation at Desired Site -- 3.4.4.1 131I for Thyroid Therapy -- 3.4.4.2 223Ra, 89Sr for Bone Metastases (Alkaline Earth Metals) -- 3.4.5 Phosphonates -- 3.4.5.1 153Sm-EDTMP, 186Re-HEDP for Bone Metastases -- 3.5 Conclusion -- References -- Part 2: Clinical Applications of Targeted Radionuclide Therapy in Cancer Control -- 4. Unconjugated Radionuclides -- 4.1 Radioiodine Therapy (131I) for Differentiated Thyroid Cancer -- 4.1.1 Introduction -- 4.1.2 Radioactive Dosing -- 4.1.3 Procedure -- 4.1.3.1 Patient Preparation |
|
4.1.3.2 Radiation Safety Aspects -- 4.1.3.3 Post-Therapy Scintigraphy -- 4.1.3.4 Avoidance of ""Stunning -- 4.1.4 Side Effects -- 4.2 Unconjugated Radionuclides for Bone Therapy -- 4.2.1 Introduction -- 4.2.2 Clinical Aspects -- 4.2.2.1 Post-Therapy Scintigraphy and Side Effects -- 4.3 Unconjugated Radionuclides for Selective Internal Radiation Therapy in Liver Tumors -- 4.3.1 Introduction -- 4.3.1.1 Types of Unconjugated Radionuclides and Microspheres -- 4.3.2 Treatment Strategies and Considerations -- 4.3.2.1 Intent of Treatment |
| Summary |
This book covers scientific, clinical, and educational aspects of radiotheranostics in cancer control. Setting the framework, the first volume defines radiotheranostics and describes the history of radionuclide therapy and theranostics, and the biology of cancer |
| Notes |
Description based upon print version of record |
|
4.3.2.2 Radiation Simulation Study and Personalized Predictive Dosimetry |
| Form |
Electronic book
|
| Author |
Stabin, Michael G
|
| ISBN |
9781003836070 |
|
1003836070 |
|
